{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:41:15Z","timestamp":1792093275764,"version":"4.4.0"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":541,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,7]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold> In man a neurokinin\u20101 (NK<jats:sub>1<\/jats:sub>) receptor antagonist has previously been shown to be ineffective in the prevention of motion\u2010induced nausea. The antiemetic efficacy of NK<jats:sub>1<\/jats:sub> receptor antagonists against chemotherapy\u2010induced emesis is, however, enhanced when combined with a 5\u2010HT<jats:sub>3<\/jats:sub> receptor antagonist. Hence the efficacy of the NK<jats:sub>1<\/jats:sub> antagonist GR205171 in combination with the 5\u2010HT<jats:sub>3<\/jats:sub> antagonist ondansetron (Zofran<jats:sup>\u2122<\/jats:sup>) was assessed in motion\u2010induced nausea.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold> GR205171 25\u2003mg i.v., with and without concomitant administration of ondansetron 8\u2003mg i.v., and hyoscine hydrobromide 0.6\u2003mg orally (positive control) were compared with placebo in a model of motion\u2010induced nausea. The study was performed to a four\u2010period, randomized, balanced, double\u2010blind, crossover design in 16\u2003healthy subjects. The end\u2010point was the exposure to the motion stimulus required to produce moderate nausea in the subjects.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold> The motion stimulus required to produce moderate nausea was significantly greater for the positive control than placebo (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). There was no significant difference between either GR205171 or GR205171 plus ondansetron and placebo (<jats:italic>P<\/jats:italic>\u2003=\u20030.648 and 0.342, respectively).<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold> The enhancement of NK<jats:sub>1<\/jats:sub> receptor antagonist antiemetic activity through combination with a 5\u2010HT<jats:sub>3<\/jats:sub> receptor antagonist is not replicated in motion\u2010induced nausea.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00221.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:39:13Z","timestamp":1047357553000},"page":"61-64","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of the neurokinin\u20101 antagonist GR205171, alone and in combination with the 5\u2010HT<sub>3<\/sub> antagonist ondansetron, hyoscine and placebo in the prevention of motion\u2010induced nausea in man"],"prefix":"10.1111","volume":"50","author":[{"given":"K.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Clemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Troakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. S.","family":"Somal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R. R.","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb05345.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90673-6"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(96)00071-7"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700888"},{"key":"e_1_2_5_6_2","first-page":"282P","article-title":"Comparison of a neurokinin\u20101 antagonist, L\u2010758,298, and scopolamine with placebo in the prevention of motion\u2010induced nausea in man","volume":"46","author":"Reid K","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400304"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.338"},{"issue":"4","key":"e_1_2_5_9_2","first-page":"687P","article-title":"Preliminary anti\u2010emetic efficacy and pharmacokinetics of the NK1 receptor antagonist GR205171 in patients receiving high dose cisplatin chemotherapy","volume":"9","author":"Fumoleau P","year":"1998","journal-title":"Ann Oncol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00606.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.817"},{"key":"e_1_2_5_12_2","unstructured":"NavariR GrallaRJ HeskethPJ et al.L\u2010754 030 a selective neurokinin\u20101 antagonist reduces cisplatin\u2010induced acute and delayed emesis: a double blind randomised trial.Proc Am Soc Clin Oncol Abstract 197 1998."},{"key":"e_1_2_5_13_2","unstructured":"Van BelleS CocquytV De SmetM et al.Comparison of a neurokinin\u20101 antagonist L\u2010758 298 to ondansetron in the prevention of cisplatin\u2010induced emesis.Proc Am Soc Clin Oncol Abstract 198 1998."},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","unstructured":"HeskethPJ GrallaRJ WebbRT et al.Randomised phase II study of the neurokinin\u20101 antagonist CJ\u201011 974 for the control of cisplatin\u2010induced emesis.Proc Am Soc Clin Oncol Abstract 199 1998.","DOI":"10.1200\/JCO.1999.17.1.338"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00221.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00221.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00221.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T15:38:02Z","timestamp":1698593882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00221.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00221.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00221.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]}}}